YOLFTbeta
PYC Therapeutics Ltd

PYC Therapeutics Ltd

PYC · AU · Healthcare / Biotechnology

1.84AUD-0.08 (-4.18%)

Price History

Full chart

Market Stats

Previous Close1.92
Open1.90
Day Range1.82 – 1.92
52-Week Range1.05 – 2.93
Volume2.54M
Market Cap2.42B
P/E (TTM)0.00
Forward P/E12.00
EPS-0.06
Dividend Yield0.00%
Beta1.08
50-Day Avg2.28
200-Day Avg1.65

About

PYC Therapeutics Limited, a clinical stage drug-development company, engages in the discovery and development of novel RNA therapeutics for the treatment of genetic diseases in Australia. It is developing PYC-003, which is in Phase1a/1b multiple ascending dose study for polycystic kidney disease; PYC-002, a Phelan McDermid Syndrome; PYC-001 for the treatment of Phelan-McDermid Syndrome; PYC-001, which is in Phase 1b multiple ascending dose study for autosomal dominant optic atrophy; and VP-001 for the treatment of retinitis pigmentosa type 11. The company was formerly known as Phylogica Limited and changed its name to PYC Therapeutics Limited in November 2019. PYC Therapeutics Limited was incorporated in 2001 and is based in Nedlands, Australia.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Rohan Hockings G.D.L.P, J.D., MBBS, MBBS (Hons.)
  • Employees0
  • HeadquartersHarry Perkins Institute of Medical Research, Nedlands, WA, Australia, 6009, Australia
  • Websitehttps://pyctx.com

Leadership

  • Dr. Rohan Hockings G.D.L.P, J.D., MBBS, MBBS (Hons.)CEO & Executive Director · b. 1983
  • Mr. Thomas UlmerChief Financial Officer · b. 1978
  • Mr. Garrett BrayChief Operating Officer
  • Dr. Janya GrainokChief Scientific Officer
  • Mr. Jonathan Riley B.Sc., L.L.B.General Counsel & Joint Company Secretary
  • Dr. Paula CunninghamChief Development Officer
  • Ms. Candice JungeChief Clinical Development Officer
  • Mr. Stephen Alan Ledger B.Com.Joint Company Secretary

Financials

Income Statement

Currency: AUD2004-06-302005-06-302006-06-302007-06-302008-06-302009-06-302010-06-302011-06-302012-06-302013-06-302014-06-302015-06-302016-06-302017-06-302018-06-302019-06-302020-06-302021-06-302022-06-302023-06-302024-06-302025-06-302026-06-30
Total Revenue-52.56K489.00K275.38K90.75K1.27M596.26K2.36M1.92M711.89K739.39K829.12K1.08K2.76M48.46K2502.40M3.07M16.04M15.81M22.06M23.49M-
Growth (%)--+830.44%-43.68%-67.05%+1304.86%-53.23%+295.56%-18.66%-62.89%+3.86%+12.14%-99.87%+256659.57%-98.25%-99.48%+958182.40%+28.33%+421.83%-1.47%+39.56%+6.51%-
Cost of Revenue188.00K43.00K137.23K272.50K572.00K1.14M1.12M3.04M3.04M3.27M3.62M3.58M122.11K4.67M81.30K130.56K547.11K622.36K839.50K882.04K1.07M1.12M1.20M
Gross Profit-52.56K-137.23K2.89K90.75K1.27M596.26K2.36M1.92M-2.55M-2.88M-2.75M-121.04K-1.91M-32.84K-130.56K1.85M2.45M15.20M14.92M22.06M23.49M-1.20M
Gross Margin-100.00%-28.06%1.05%100.00%100.00%100.00%100.00%100.00%-358.88%-389.52%-331.60%-11248.98%-69.11%-67.76%-52222.40%77.16%79.76%94.77%94.42%100.00%100.00%-
Operating Expense-1.79M3.94M4.70M5.66M4.98M5.26M6.08M5.98M3.55M2.26M2.28M5.83M2.34M9.74M6.97M11.55M24.28M45.41M54.09M60.92M77.12M81.47M
Operating Income--1.74M-4.08M-4.70M-5.57M-3.70M-4.66M-3.72M-4.07M-6.10M-5.14M-5.03M-5.95M-4.25M-9.77M-7.10M-9.70M-21.83M-30.21M-39.16M-38.86M-53.63M-82.67M
Operating Margin--3312.50%-833.70%-1705.17%-6141.81%-290.41%-782.30%-157.63%-211.95%-857.51%-694.64%-607.06%-553065.06%-153.89%-20157.14%-2840840.00%-404.97%-710.16%-188.29%-247.77%-176.15%-228.26%-
EBITDA--1.70M-3.59M-4.67M-5.52M-3.59M-4.60M-3.56M-3.87M-5.04M-4.92M-4.82M-6.10M-4.20M-9.64M-6.97M-8.89M-21.04M-29.39M-38.25M-54.55M-52.88M-81.47M
EBITDA Margin--3232.01%-734.64%-1695.62%-6087.29%-281.47%-771.07%-151.08%-201.72%-708.63%-665.67%-581.47%-567145.26%-151.89%-19889.37%-2788618.00%-370.88%-684.36%-183.23%-242.01%-247.30%-225.06%-
Net Income--1.59M-3.99M-3.89M-4.48M-4.49M-4.57M-3.61M-3.90M-3.44M-3.26M-2.99M-3.98M-1.95M-7.43M-4.08M-6.82M-17.77M-13.86M-22.79M-37.73M-50.30M-43.34M
Net Income Margin--3020.25%-816.25%-1412.09%-4940.87%-352.25%-766.92%-152.86%-203.53%-483.17%-440.59%-360.80%-369765.06%-70.61%-15340.48%-1631906.80%-284.77%-577.93%-86.41%-144.18%-171.02%-214.11%-
R&D-407.78K1.38M1.34M2.28M1.70M1.89M3.79M3.72M4.04M4.18M4.12M4.86M4.67M6.96M4.51M5.88M14.00M24.03M35.15M56.41M70.05M73.98M
R&D as % of Total Revenue-775.90%281.47%487.68%2516.46%133.42%317.31%160.69%193.91%567.81%564.86%496.36%451236.06%169.11%14367.81%1805360.80%245.35%455.50%149.79%222.36%255.71%298.16%-
Interest Expense000000000000000118.21K42.92K38.82K32.59K27.29K49.21K62.22K40.46K
Interest Expense % of Total Revenue-0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%47285.20%1.79%1.26%0.20%0.17%0.22%0.26%-

Balance Sheet

Currency: AUD2004-06-302005-06-302006-06-302007-06-302008-06-302009-06-302010-06-302011-06-302012-06-302013-06-302014-06-302015-06-302016-06-302017-06-302018-06-302019-06-302020-06-302021-06-302022-06-302023-06-302024-06-302025-06-302026-06-30
Total Assets1.17M6.08M2.83M3.53M3.52M3.49M1.57M5.66M3.50M2.26M4.52M1.79M7.27M10.35M3.42M6.70M31.55M57.94M45.35M37.17M91.24M183.28M708.52M
Total Liabilities628.00K303.61K717.91K1.34M824.36K1.58M2.01M1.31M801.17K1.07M805.48K823.80K1.44M1.49M1.77M401.87K1.35M4.02M5.15M8.72M10.18M13.27M15.18M
Total Equity546.00K5.78M2.11M2.20M2.69M1.91M-437.08K4.35M2.69M1.19M3.72M962.03K5.83M8.86M1.65M6.30M28.45M53.04M39.35M27.75M80.50M169.57M693.33M
Cash791.00K5.51M2.64M3.37M3.23M3.07M1.28M5.20M2.78M1.81M4.02M1.48M7.07M9.94M3.15M1.66M7.24M18.44M29.11M15.57M66.87M153.05M53.56M
Total Debt--12.70K9.68K7.09K1.03M1.24M--------798.14K798.15K730.35K943.77K315.49K1.11M1.02M624.99K
Net Debt--5.51M-2.63M-3.36M-3.22M-2.05M-43.35K-5.20M-2.78M-1.81M-4.02M-1.48M-7.07M-9.94M-3.15M-1.66M-6.44M-17.70M-28.17M-15.26M-65.76M-152.03M-52.94M

Cash Flow

Currency: AUD2004-06-302005-06-302006-06-302007-06-302008-06-302009-06-302010-06-302011-06-302012-06-302013-06-302014-06-302015-06-302016-06-302017-06-302018-06-302019-06-302020-06-302021-06-302022-06-302023-06-302024-06-302025-06-302026-06-30
Operating Cash Flow28.00K-1.33M-2.81M-3.09M-4.97M-3.88M-3.63M-2.94M-4.15M-2.32M-3.20M-2.48M-3.17M-1.88M-6.71M-5.13M-5.75M-11.79M-21.78M-24.42M-38.59M-51.56M-44.52M
Investing Cash Flow--224.71K-52.49K-67.25K-130.47K-5.42K-143.18K-193.04K-353.85K-256.98K-195.82K-64.47K-25.38K-3.46K-210.58K-4.98M-13.77M-15.52M32.68M-477.12K-307.04K-975.40K-616.16M
Financing Cash Flow896.00K6.27M-5.44K3.89M4.97M3.73M1.98M7.05M2.09M1.60M5.61M8.79M8.79M4.75M125.21K8.62M25.11M38.56M-182.36K11.44M90.19M138.66M563.22M
Capital Expenditure3.00K224.71K52.49K67.25K130.47K5.42K158.78K193.04K353.85K256.98K195.82K64.47K26.78K4.54K210.58K457.54K106.10K591.03K386.91K491.12K307.04K975.40K531.39K
Free Cash Flow--1.56M-2.86M-3.16M-5.10M-3.88M-3.79M-3.14M-4.51M-2.57M-3.40M-2.55M-3.19M-1.89M-6.92M-5.58M-5.85M-12.38M-22.17M-24.91M-38.90M-52.54M-45.05M
Dividends Paid----------------23.49M36.26M-10.46M---
FCF to OCF-116.88%101.87%102.18%102.62%100.14%104.38%106.56%108.52%111.10%106.12%102.60%100.85%100.24%103.14%108.93%101.85%105.01%101.78%102.01%100.80%101.89%101.19%
Dividend Paid to FCF-----------------401.15%-292.86%--42.01%---

Earnings

Report DateFeb 29, 2016Aug 30, 2016Feb 28, 2017Sep 22, 2017Feb 28, 2018Aug 31, 2018Feb 28, 2019Aug 30, 2019Feb 28, 2020Aug 31, 2020Feb 26, 2021Aug 31, 2021Feb 28, 2022Sep 23, 2022Feb 28, 2023Feb 27, 2025Aug 27, 2025
EPS Estimate0.000.000.000.000.000.000.000.000.000.000.000.000.000.00-0.00-0.05
EPS Actual0.000.000.000.000.000.000.000.000.000.000.000.000.000.00-0.01-0.05-0.05
Surprise----------------0.00%
Timing-------------Pre-marketAfter-hours-Pre-market

Key Statistics & Ratios

Market Cap2.42B
Enterprise Value2.42B
Trailing P/E0.00
Forward P/E12.00
PEG Ratio0.00
Price / Sales93.08
Price / Book4.13
EPS-0.06
Book Value0.705
Revenue (TTM)25.99M
Gross Profit (TTM)25.99M
EBITDA-56.59M
Profit Margin-166.73%
Operating Margin-188.25%
Return on Equity-10.14%
Return on Assets-8.05%
Shares Outstanding983.51M
Shares Float618.49M
Beta1.08
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Stock Splits

  • Feb 4, 2026128:125
  • Feb 19, 2025918:913
  • Nov 15, 20241:10
  • Mar 18, 202485:84
  • Oct 22, 2020407:404
  • Nov 4, 2019372:365
  • Jul 7, 20156:5
  • Dec 5, 201385:81
  • Sep 2, 201081:80